HomepageRDY • NYSE
add
Dr Reddy's Laboratories Ltd
Vorige slotkoers
$Â 13,61
Dag-range
$Â 13,65 - $Â 13,88
Jaar-range
$Â 12,26 - $Â 16,17
Beurswaarde
10,87Â mld. USD
Gem. volume
1,53Â mln.
Koers/winst
18,54
Dividendrendement
0,66%
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (INR) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 87,27Â mld. | 4,41% |
Bedrijfskosten | 32,48Â mld. | 7,03% |
Netto inkomsten | 12,10Â mld. | -14,40% |
Netto winstmarge | 13,86 | -18,04% |
Winst per aandeel | 14,77 | -12,79% |
EBITDA | 19,54Â mld. | -16,58% |
Effectief belastingtarief | 22,90% | — |
Balans
Totale activa
Totale passiva
| (INR) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 82,59Â mld. | 37,83% |
Totale activa | 562,90Â mld. | 17,01% |
Totale passiva | 187,14Â mld. | 17,34% |
Totaal aandelenvermogen | 375,76 mld. | — |
Uitstaande aandelen | 832,57 mln. | — |
Koers-boekwaardeverhouding | 0,03 | — |
Rendement op activa | 6,48% | — |
Rendement op kapitaal | 8,29% | — |
Kasstroom
Nettomutatie in liquide middelen
| (INR) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 12,10Â mld. | -14,40% |
Operationele kasstroom | 10,91Â mld. | 64,77% |
Kasstroom uit beleggingen | -10,29Â mld. | -88,57% |
Kasstroom uit financiering | 7,78Â mld. | 1.218,14% |
Nettomutatie in liquide middelen | 8,75Â mld. | 400,92% |
Vrije kasstroom | -672,75Â mln. | -26,52% |
Over
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
CEO
Opgericht
1984
Hoofdvestiging
Website
Werknemers
27.811